KDM6B inhibition modulates monocyte activation and alleviates IMQ-psoriasis skin inflammation
Aman DamaraiD, Najla AbassiiD, Delia Mihaela Mihoc, Mahsa Nastaranpour, Pauline Kraft, Tina Sarkar, Carsten DeppermanniD, Johannes U. MayeriD, Stephan GrabbeiD, Michael DelacheriD, Fédérico MariniiD, Fatemeh Zare ShahnehiD
Abstract
Inflammatory monocytes are increasingly recognized as key amplifiers of psoriasis, yet the epigenetic drivers of their pathogenic signature remain unclear. Here, we demonstrate that the histone demethylase KDM6B is markedly upregulated and catalytically active in classical monocytes during the imiquimod (IMQ)-induced psoriasis model. This is associated with reduced levels of the repressive histone mark H3K27me3, an epigenetic modification linked to chromatin compaction and transcriptional silencing, at the Il1b, Tnf, Pgam1, Pgk1, and Aldoa promoters, together with an enhanced inflammatory and glycolytic gene signature. Pharmacological blockade of KDM6B after disease onset using GSK-J4, a cell-permeable prodrug that is intracellularly converted to the active KDM6B inhibitor GSK-J1, restores H3K27me3 at inflammatory and metabolic loci, suppresses Il1b/Tnf transcription, normalizes bioenergetic profiles, and reduces monocyte and neutrophil recruitment to the inflamed skin. Single-cell transcriptomic profiling further reveals that KDM6B inhibition represses cytokine-mediated signaling, glycolysis, and chemotaxis pathways in monocytes, yet enriches antigen presentation modules, consistent with a shift toward a homeostatic, antigen-presenting surveillance program in myeloid cells and a Treg-supportive milieu. Collectively, our data identify KDM6B as an epigenetic-metabolic switch that sustains monocyte-driven inflammation in the IMQ-induced psoriasis model. Importantly, we provide preclinical evidence that targeting KDM6B can reduce maladaptive inflammatory response even in progressed diseases. These findings propose KDM6B inhibitors as a promising adjunct to current biologics for psoriasis and other myeloid-driven autoinflammatory disorders. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=178 HEIGHT=200 SRC="FIGDIR/small/682023v1_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@efef15org.highwire.dtl.DTLVardef@395983org.highwire.dtl.DTLVardef@123e832org.highwire.dtl.DTLVardef@615f84_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Gelsolin Counteracts ER Stress-Driven Inflammatory Circuits in Psoriasis-like Dermatitis
Daisuke Ori, Haruna Okude, … Taro Kawai·bioRxiv·Nov 20, 2025
- The Mitochondria-Modulating Small Molecule TEM1657 Suppresses NFKBIZ Pathway and Resolves Th17-Driven Psoriatic Inflammation
Preeti Gautam, Aleksander Salwiński, … David Moulin·bioRxiv·Oct 10, 2026
- Downregulation of Semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis
Miki Kume, Hanako Koguchi‐Yoshioka, … Rei Watanabe·eLifePeer-reviewed·Dec 31, 2024
- Prolactin links psychological stress to psoriasis via a fibroblast-chemokine pathway
Huiyao Ge, Shiyao Zhou, … Yong Liang·bioRxiv·Oct 11, 2025
- Disease context dictates the cellular targets of IL-17 in inflammatory skin disease
Kellen J. Cavagnero, Fengwu Li, … Richard L. Gallo·Journal of Investigative DermatologyPeer-reviewed·Jul 1, 2026
- Single-cell Landscape of Immune Cells in Blood and Skin in Psoriasis
Jingwen Deng, Michel A.M. Olde Nordkamp, … Bram Gerritsen·bioRxiv·Sep 17, 2024